Avidity Biosciences Inc

RNA is in a Stage 2 advancing corrective reset range with short‐term EMAs now acting as support. The medium‐term bias remains bullish anchored by the longer‐term uptrend, but short‐term timing is neutral. We will patient wait for pullbacks into the EMAs around the lower bound of the range to establish a structured entry opportunity rather than executing immediately.

• ↑77% 13F ownership signals robust institutional backing.
• ↑Cantor Fitzgerald initiated Overweight with $25 target.
• ↓Negative earnings yield and weak profitability curb returns.